BRIEF — Journal article will grab the attention of allergists globally, says ASIT

Belgian allergy specialist ASIT Biotech has highlighted the publication in the journal ALLERGY of the results of a Phase III clinical trial to assess the clinical efficacy of the product candidate gp-ASIT+ for the immunotherapy treatment of grass pollen-induced rhinitis in real life.

These results showed that a short treatment with gp-ASIT+ induced a convincing and statistically significant reduction in the combined score of symptoms and medication intake during natural exposure to grass pollens.

Thierry Legon, chief executive of ASIT Biotech, said: “This new article in ALLERGY follows the publications of the full clinical development - Phase I to Phase III – of our flagship product candidate, gp-ASIT+.

“It will once again draw the attention of the global community of allergists onto the remarkable properties of gp-ASIT. The phase III results have demonstrated for the first time ever that allergen peptides are able to reduce, in real life, allergic patients’ symptoms and drug intake after only three weeks of treatment with gp-ASIT while other products require several months or even years to reach the same effect.”